Ozmosi | Cediranib Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Cediranib

Alternative Names: cediranib, recentin, azd2171
Clinical Status: Active
Latest Update: 2025-10-27
Latest Update Note: Clinical Trial Update

Product Description

Cediranib is a potent small molecule vascular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK) inhibitor of all three VEGF receptors (VEGFR-1, 2 and 3) at nanomolar concentrations.  (Sourced from: https://nciformulary.cancer.gov/available_agents/Cediranib.htm)

Mechanisms of Action: VEGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cediranib

Countries in Clinic: Austria, Canada, France, Germany, Israel, Puerto Rico, South Korea, Spain, United States

Active Clinical Trial Count: 5

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Adenocarcinoma|Carcinosarcoma|Clear Cell Adenocarcinoma|Colorectal Cancer|Endometrial Cancer|Endometrioid Carcinoma|Leiomyosarcoma|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma|Transitional Cell Carcinoma|Uveal Melanoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT03851614

DAPPER

P2

Active, not recruiting

Colorectal Cancer|Pancreatic Cancer|Adenocarcinoma|Leiomyosarcoma

2026-01-01

12%

2025-04-01

Primary Endpoints

NCT03660826

NCI-2017-01672

P2

Active, not recruiting

Adenocarcinoma|Endometrioid Carcinoma|Endometrial Cancer|Carcinosarcoma

2024-12-06

2025-10-10

Patient Enrollment|Primary Endpoints|Treatments

NCT03334617

HUDSON

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2024-09-13

12%

2025-10-28

2019-001045-40

CEDUVEAL-M

P2

Active, not recruiting

Uveal Melanoma

2023-03-02

2022-03-13

Treatments

NCT04739800

NCI-2021-00615

P2

Active, not recruiting

Ovarian Cancer|Transitional Cell Carcinoma|Serous Cystadenocarcinoma|Peritoneal Cancer|Endometrioid Carcinoma|Mucinous Cystadenocarcinoma|Mucinous Adenocarcinoma|Clear Cell Adenocarcinoma

2023-01-26

2024-11-27